Literature DB >> 10496924

Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis.

J S Plested1, K Makepeace, M P Jennings, M A Gidney, S Lacelle, J Brisson, A D Cox, A Martin, A G Bird, C M Tang, F M Mackinnon, J C Richards, E R Moxon.   

Abstract

We investigated the conservation and antibody accessibility of inner core epitopes of Neisseria meningitidis lipopolysaccharide (LPS) because of their potential as vaccine candidates. An immunoglobulin G3 murine monoclonal antibody (MAb), designated MAb B5, was obtained by immunizing mice with a galE mutant of N. meningitidis H44/76 (B. 15.P1.7,16 immunotype L3). We have shown that MAb B5 can bind to the core LPS of wild-type encapsulated MC58 (B.15.P1.7,16 immunotype L3) organisms in vitro and ex vivo. An inner core structure recognized by MAb B5 is conserved and accessible in 26 of 34 (76%) of group B and 78 of 112 (70%) of groups A, C, W, X, Y, and Z strains. N. meningitidis strains which possess this epitope are immunotypes in which phosphoethanolamine (PEtn) is linked to the 3-position of the beta-chain heptose (HepII) of the inner core. In contrast, N. meningitidis strains lacking reactivity with MAb B5 have an alternative core structure in which PEtn is linked to an exocyclic position (i.e., position 6 or 7) of HepII (immunotypes L2, L4, and L6) or is absent (immunotype L5). We conclude that MAb B5 defines one or more of the major inner core glycoforms of N. meningitidis LPS. These findings support the possibility that immunogens capable of eliciting functional antibodies specific to inner core structures could be the basis of a vaccine against invasive infections caused by N. meningitidis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496924      PMCID: PMC96899          DOI: 10.1128/IAI.67.10.5417-5426.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  68 in total

Review 1.  Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A.

Authors:  M A Apicella; J M Griffiss; H Schneider
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

2.  Physical heterogeneity of neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression.

Authors:  J M Griffiss; J P O'Brien; R Yamasaki; G D Williams; P A Rice; H Schneider
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

3.  Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development.

Authors:  S Rune Andersen; J Kolberg; E A Høiby; E Namork; D A Caugant; L Oddvar Frøholm; E Jantzen; G Bjune
Journal:  Microb Pathog       Date:  1997-09       Impact factor: 3.738

4.  Functional relationships of the genetic locus encoding the glycosyltransferase enzymes involved in expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis.

Authors:  W Wakarchuk; A Martin; M P Jennings; E R Moxon; J C Richards
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

5.  NMR and molecular dynamics studies of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives.

Authors:  J R Brisson; S Uhrinova; R J Woods; M van der Zwan; H C Jarrell; L C Paoletti; D L Kasper; H J Jennings
Journal:  Biochemistry       Date:  1997-03-18       Impact factor: 3.162

6.  Cloning and molecular analysis of the Isi1 (rfaF) gene of Neisseria meningitidis which encodes a heptosyl-2-transferase involved in LPS biosynthesis: evaluation of surface exposed carbohydrates in LPS mediated toxicity for human endothelial cells.

Authors:  M P Jennings; M Bisercic; K L Dunn; M Virji; A Martin; K E Wilks; J C Richards; E R Moxon
Journal:  Microb Pathog       Date:  1995-12       Impact factor: 3.738

7.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

8.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Phase variation of gonococcal pili by frameshift mutation in pilC, a novel gene for pilus assembly.

Authors:  A B Jonsson; G Nyberg; S Normark
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

10.  Genetic locus for the biosynthesis of the variable portion of Neisseria gonorrhoeae lipooligosaccharide.

Authors:  E C Gotschlich
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  26 in total

1.  Structural and immunochemical characterization of the lipooligosaccharides expressed by Neisseria subflava 44.

Authors:  Y Tong; V Reinhold; B Reinhold; B Brandt; D C Stein
Journal:  J Bacteriol       Date:  2001-02       Impact factor: 3.490

2.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: immunology of glycoconjugates with high carbohydrate loading.

Authors:  Andrew D Cox; Frank St Michael; Dhamodharan Neelamegan; Suzanne Lacelle; Chantelle M Cairns; Marzia M Giuliani; Alessia Biolchi; J Claire Hoe; E Richard Moxon; James C Richards
Journal:  Glycoconj J       Date:  2010-10-05       Impact factor: 2.916

3.  Phosphorylation of the lipid A region of meningococcal lipopolysaccharide: identification of a family of transferases that add phosphoethanolamine to lipopolysaccharide.

Authors:  Andrew D Cox; J Claire Wright; Jianjun Li; Derek W Hood; E Richard Moxon; James C Richards
Journal:  J Bacteriol       Date:  2003-06       Impact factor: 3.490

4.  Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.

Authors:  Margaret Anne J Gidney; Joyce S Plested; Suzanne Lacelle; Philip A Coull; J Claire Wright; Katherine Makepeace; Jean-Robert Brisson; Andrew D Cox; E Richard Moxon; James C Richards
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.

Authors:  Yanwen Li; Yao-hui Sun; Cathy Ison; Myron M Levine; Christoph M Tang
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 6.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

7.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading.

Authors:  Andrew D Cox; Frank St Michael; Dhamodharan Neelamegan; Suzanne Lacelle; Chantelle Cairns; James C Richards
Journal:  Glycoconj J       Date:  2010-03-26       Impact factor: 2.916

8.  Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: conjugates based on core oligosaccharides.

Authors:  F St Michael; C M Cairns; A L Filion; A Biolchi; B Brunelli; M Giuliani; J C Richards; A D Cox
Journal:  Glycoconj J       Date:  2013-09-07       Impact factor: 2.916

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Neisseria meningitidis escape from the bactericidal activity of a monoclonal antibody is mediated by phase variation of lgtG and enhanced by a mutator phenotype.

Authors:  Christopher D Bayliss; J Claire Hoe; Katherine Makepeace; Patricia Martin; Derek W Hood; E Richard Moxon
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.